GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Breakthrough for MASH Treatment

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.

GlaxoSmithKline (GSK) is embarking on a pivotal clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)’. The study aims to assess the safety and tolerability of Efimosfermin Alfa in individuals with MASH, a condition linked to non-alcoholic fatty liver disease. This research is significant as it addresses a growing health concern with limited treatment options.

The intervention being tested is Efimosfermin Alfa, a drug designed to treat MASH by potentially reducing liver inflammation and fibrosis. The study includes two experimental groups receiving different doses of Efimosfermin Alfa and a placebo group for comparison.

The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Participants and investigators are unaware of group assignments to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new insights into managing MASH.

Key dates for the study include its start date on October 15, 2025, with the last update submitted on October 24, 2025. These dates are crucial as they mark the study’s initiation and the most recent information available, indicating that the study is not yet recruiting participants.

This study’s update could influence GSK’s stock performance, as successful results may enhance investor confidence and market position. The pharmaceutical industry is closely watching developments in MASH treatments, given the unmet medical need and potential market size.

The study is ongoing, with further details accessible on the ClinicalTrials portal.